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Abstract 22 
The v-rel oncoprotein encoded by reticuloendotheliosis virus T strain (Rev-T) is a member of 23 
the rel/NF-κB family of transcription factors capable of transformation of primary chicken 24 
spleen and bone marrow cells. Rapid transformation of avian haematopoietic cells by v-rel 25 
occurs through a process of deregulation of multiple protein-encoding genes through its direct 26 
effect on their promoters. More recently, upregulation of oncogenic miR-155 and its 27 
precursor pre-miR-155 were demonstrated in Rev-T-infected chicken embryo fibroblast 28 
cultures as well as Rev-T-induced B-cell lymphomas. Through electrophoresis mobility shift 29 
assay and reporter analysis on gga-miR-155 promoter, we show that the v-rel-induced miR-30 
155 overexpression occurs by the direct binding to one of the putative NF-κB binding sites. 31 
Using v-rel-induced transformation model on chicken embryonic splenocyte cultures, we 32 
could demonstrate dynamic increase in miR-155 levels during the transformation. 33 
Transcriptome profiles of lymphoid cells transformed by v-rel showed upregulation of miR-34 
155 accompanied by downregulation of a number of putative miR-155 targets such as Pu.1 35 
and CEBPβ. We also show that v-rel can rescue the suppression of miR-155 expression 36 
observed in Marek’s disease virus-transformed cell lines, where its functional viral homolog 37 
MDV-miR-M4 is overexpressed. Demonstration of gene expression changes affecting major 38 
molecular pathways including organismal injury and cancer in avian macrophages transfected 39 
with synthetic mature miR-155 underline its potential direct role in transformation. Our study 40 
suggests that v-rel-induced transformation involves complex set of events mediated by the 41 
direct activation of NF-κB targets together with the inhibitory effects on miRNA targets.    42 
Keywords: v-rel , NF-κB, miR-155, transformation 43 
44 
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Introduction 45 
The rel/NF-κB family of transcription factors (1, 2) play a key role in the control of cell 46 
proliferation and apoptosis, two functions critical in cancer. The involvement of rel/NF-κB in 47 
malignancy is best demonstrated by the acute oncogenicity of their viral derivative, v-rel, 48 
first identified in reticuloendotheliosis virus T (Rev-T) strain (3, 4). Rev-T is an acutely 49 
transforming variant of REV, the aetiological agent of reticuloendotheliosis in birds, carrying 50 
the viral oncogene v-rel, a variant of the turkey cellular proto-oncogene c-rel (5-7). Because 51 
of the rapidity and efficiency of transformation of the cells, the v-rel provides a valuable 52 
model for studying the role of rel/NF-κB family in neoplastic transformation and cancer. The 53 
v-rel-mediated transformation occurs predominantly through the modulation of transcription 54 
of rel/NF-κB targets (8-10), the examples of which include AP-1 (11, 12), IRF-4 (13), 55 
SH3BGRL (14), TGFβ/Smad (15) and telomerase reverse transcriptase (TERT) subunit (16). 56 
More recently, repression of BLNK and BCAP proteins (17) and a novel interaction of 57 
CAPERα and the transactivating domain of v-rel (18) were shown to be important for 58 
lymphocyte transformation by the v-rel oncoprotein.  59 
Several studies have also implicated microRNAs (miRNAs) as key mediators of a number of 60 
cell regulatory processes including the induction of cancer (19-21). Among the numerous 61 
miRNAs expressed in hematopoietic cells, miR-155 was shown to have the most wide 62 
ranging effects on the biology of lymphocytes (22-25). It is processed from a primary 63 
transcript, known as ‘Bic’ (B-cell integration cluster), whose upstream region was originally 64 
found to be a frequent site of integration of the avian leukosis virus in lymphomas (26). A 65 
number of recent miRNA profiling studies have shown elevated levels of miR-155 in a wide 66 
array of cancers including lymphomas (27-30).  67 
In a recent study on chicken embryo fibroblast (CEF) cultures infected with 68 
reticuloendotheliosis virus (Rev) HA1101 strain, differential expression of a number of genes 69 
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leading to changes in several  signalling pathways were reported (31). We and others have 70 
shown upregulation of miR-155 in Rev-T-transformed cell lines and CEF (32, 33). For 71 
further analysis of the global changes in miRNA profiles induced by v-rel, we used an in 72 
vitro model of v-rel-induced transformation of embryonic splenocytes to demonstrate the 73 
sequential upregulation of miR-155 during the transformation process. Our studies confirm 74 
that v-rel-mediated upregulation of gga-miR-155 occurs through the direct binding to at least 75 
one of the putative NF-κB sites on the Bic/miR-155 promoter. Analysis of the gene 76 
expression changes in the v-rel-transformed cells further demonstrated downregulation of a 77 
number of known miR-155 targets potentially affecting a number of important biological 78 
pathways. Demonstration of the targeting of a number of cancer-related genes in chicken 79 
macrophages overexpressing miR-155 demonstrated the importance of this miRNA as a 80 
major regulator of v-rel-induced transformation. 81 
  82 
Results 83 
Upregulation of miR-155 in Rev-T transformed cell lines. During the analysis of the 84 
global changes in miRNA expression in chicken lymphocyte lines transformed by avian 85 
oncogenic viruses, we observed that miR-155 is overexpressed in v-rel-transformed chicken 86 
lymphocytes, compared to the normal spleen cells and MDV-transformed cell lines (32). For 87 
confirmation of the higher expression of miR-155 in v-rel-transformed cells, we examined 88 
Rev-T-transformed cell lines AVOL-1, AVOL-2, AVOL-3 and RIR-Rev-T cells by Northern 89 
blot analysis. An ALV transformed B-cell line HP45 was used as positive control where miR-90 
155 is upregulated due to insertional activation and normal spleen cells which doesn’t express 91 
detectable levels of miR-155 was used as negative control. High levels of miR-155 transcripts 92 
were readily observed in all Rev-T transformed cell lines (Fig 1).  93 
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v-rel binds to the NF-κB sites in the Bic/miR-155 promoter. Having demonstrated the 94 
upregulation of miR-155 in Rev-T transformed cells, we examined the potential mechanisms 95 
of miR-155 overexpression by v-rel. Analysis of the chicken Bic/miR-155 promoter sequence 96 
for potential transcription factor binding sites using the program TFSEARCH (34) identified 97 
a number of transcription factor binding sites, including two putative NF-κB sites (NF-κB1 & 98 
NF-κB2) located at positions -581 and -66 respectively (relative to the transcription start site). 99 
In order to establish that v-rel binds directly to the putative NF-κB sites in the Bic/miR-155 100 
promoter, electrophoresis mobility shift assay was carried out using recombinant GST-v-rel 101 
fusion protein. Briefly, purified GST-v-rel protein was incubated with dsDNA 102 
oligonucleotides probe spanning the two putative NF-κB sites. The intense shifted bands 103 
were observed with incubation of GST-v-rel and wild type labelled probes for both sites (lane 104 
2, Fig 2A). The bands are competed by an excess of cold competitor (lane 3, Fig 2A), but not 105 
the same amount of a mutant competitor that is not bound by v-rel protein (lane 4, Fig 2A).   106 
NF-κB site 2 in Bic/miR-155 promoter is required for miR-155 activation.  Having 107 
demonstrated the direct binding of v-rel to the NF-κB sites, we next examined the possible 108 
contribution of these elements in mediating Bic regulation. To this end, we carried out 109 
reporter assays to examine the ability of v-rel to drive the expression of renilla luciferase 110 
reporter gene using constructs containing the wild type or the mutant chicken Bic/miR-155 111 
promoter. For this, the chicken Bic/miR-155 promoter region extending from -1829 to +3 112 
nucleotides from transcription start site (+1) was cloned upstream renilla luciferase gene of 113 
psiCHECK™-2 vector (Promega) to replace the SV40 promoter generating the reporter 114 
construct pBic-WT. Mutagenesis of the two NF-κB sites was carried out by overlapping PCR 115 
generating pBic-M1, pBic-M2 and pBic-M1M2 constructs, where the NF-κB1, NF-κB2 or 116 
both sites respectively, were mutated (Fig 2B). For the reporter assay, each of the reporter 117 
and pcDNA3-v-rel constructs were co-transfected into DF-1 cells and the luciferase 118 
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expression was assayed 48 hours later using the Dual-Glo Luciferase Assay System 119 
(Promega) following manufacturer’s instructions. As shown in Fig 2C, mutation of the first 120 
NF-κB site (pBic-M1) did not show obvious changes in the luciferase levels compared to the 121 
wild type promoter (pBic-WT) construct. In contrast, mutation of the second NF-κB site 122 
(pBic-M2) decreased the promoter activity by 63% compared to that of the pBic-WT, 123 
suggesting that the v-rel-mediated transactivation occurs mainly through this NF-κB site.  124 
The promoter activity of double mutant pBic-M1M2 construct was similar to that of pBic-M2 125 
further confirming that the second NF-κB site in the Bic/miR-155 promoter is important for 126 
the v-rel-mediated upregulation of miR-155.   127 
v-rel relieves the inhibition of miR-155 expression in MSB-1 cells. We have previously 128 
shown that miR-155 is consistently downregulated in MDV-transformed tumours and cell 129 
lines (32). Although the mechanisms for this downregulation are not known, this could be 130 
due to the complementation of miR-155 functions by the high levels of the viral homolog 131 
MDV-miR-M4 expressed in these cells. We wanted to examine whether the downregulation 132 
of miR-155 in MDV transformed cell lines can be rescued by expressing v-rel in these cells. 133 
RCAS(A)-v-rel-GFP virus stocks were used for transduction of v-rel into MSB-1 and 265L, 134 
where the GFP marker allowed sorting of the infected cells. Analysis of the sorted cells by 135 
Western blotting showed expression of v-rel-GFP in both infected MSB-1 and 265L but not 136 
in uninfected cells (Fig 3A). Expression of v-rel increased the level of miR-155 expression 137 
by approximately 700-fold in MSB-1 cells and by about 900-fold in 265L cells which is 138 
much higher than the miR-155 level in untransformed CD4+ cells (Fig 3B), demonstrating 139 
that ectopic expression of v-rel can induce expression of miR-155 in avian lymphoid cells.  140 
Induction of miR-155 is accompanied by downregulation potential targets. For further 141 
analysis of the dynamic global changes in miRNA profiles during v-rel-induced 142 
transformation, we examined the changes in RCAS(A)-v-rel-infected chicken embryonic 143 
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splenocytes undergoing transformation. Induction of v-rel in these cells resulted in rapid 144 
transformation resulting in the appearance of continuously proliferating cell lines usually in 145 
8-10 days. The dynamic changes of miR-155 expression during the transformation process of 146 
splenocytes measured by qRT-PCR are shown in Fig 4A. Quite clearly, miR-155 is 147 
significantly upregulated during the time-course of v-rel transformation, with levels showing 148 
increases of 5 fold (day 1), 6 fold (day 4), 50 fold at day 7,  150 fold at day 9 and nearly 1500 149 
fold at day 14, as compared with the level at day 0.  150 
In order to assess the simultaneous changes in gene expression during transformation, we 151 
carried out the transcriptome analysis using the chicken Affymetrix platform on the RNA 152 
samples extracted from these cells.  To focus on miRNA-induced repression of gene 153 
expression, we used the Bioconductor package Limma (35) to extract 1242 genes that showed 154 
significant downregulation at day 14 compared to day 0.  Table 1 shows the top 20 155 
statistically enriched predicted miRNA targets in this list.  Of the 1242 downregulated genes, 156 
73 are predicted targets of gga-miR-155 (Fig 4B) making it the top hit of the most enriched 157 
miRNA targets.  Analysis also showed that the enrichment of the targets of other miRNAs 158 
such as gga-miR-9*, gga-miR-217, gga-miR-19a and gga-miR-23b were also significant. 159 
These data highlighted the importance of miR-155 and other miRNAs in v-rel induced 160 
transformation. MiR-155 is a well-studied oncogene of hematopoietic cells. Considering the 161 
complexity of targets analysis in v-rel induced transformation system as lots of miRNAs and 162 
mRNAs are affected by v-rel, we overexpressed miR-155 in chicken macrophages derived 163 
from line 0 chicken by transfection of miR-155 mimics into bone-marrow derived 164 
macrophages. ‘Allstars’ negative control (Qiagen) was used as control in an attempt to get a 165 
cleaner result on miR-155 targets. The RNA extracted from transfected cells were analysed 166 
by deep sequencing. The significant down regulated genes with miR-155 target sites in 167 
3’UTR were subject to the pathway analysis using Ingenuity Pathway Analysis tool. As 168 
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shown in Fig 5, several potential miR-155 targets are involved in a number of diseases and 169 
cellular processes. The number of cancer-related genes targeted by miR-155 ranks the second 170 
implicating the importance of miR-155 as a regulator in disease pathogenesis, particularly in 171 
tumorigenesis.   172 
 173 
Discussion 174 
The Rev-T avian retrovirus encodes the v-rel oncoprotein, which is a member of the Rel/NF-175 
κB transcription factor family. Although Rel/NF-κB transcription factors have been 176 
associated with oncogenesis in mammals, v-rel is the only member of this family that is 177 
oncogenic in animal systems. Due to its pervasive role in oncogenesis, there is great interest 178 
in NF-κB signalling, and v-rel provides a valuable model for studying NF-κB signalling in 179 
lymphoid cell cancers because of its ability to transform chicken lymphoid cells (12, 15).  In 180 
this study, we demonstrate that v-rel can readily induce transformation of lymphocyte 181 
populations, and the establishment of CD4+ T-cell (AVOL-1) and B-cell (AVOL-2) lineages 182 
suggested that v-rel-induced transformation function is not restricted to specific lineages.  183 
In addition to the changes in protein-coding genes, many changes in the miRNA profiles also 184 
occur in v-rel transformed cells, and one of the miRNAs expressed at significantly higher 185 
levels in v-rel-derived tumor cell lines such as KBMC and CM758 is gga-miR-155 (33). 186 
Higher expression of miR-155 is reported in a number of haematopoietic malignancies (36-187 
40). The precursor of miR-155, termed c-Bic, was first observed to co-operate with myc in 188 
chicken B-cell lymphomas induced by avian leukosis proviral integrations (26, 41). Southern 189 
blot hybridization of genomic DNA from AVOL-1 and AVOL-2 cells showed no evidence of 190 
genomic rearrangements in Bic loci (data not shown) discounting insertional activation of 191 
miR-155 in these cell lines. It is known that miR-155 can also be induced by a variety of 192 
immune cell stimuli such as TLR ligands, TNF-α, IFN-β and other antigens (41-45). A 193 
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conserved AP-1 element in the human Bic/miR-155 promoter was shown to be essential for 194 
some of these functions (46). Transcriptional regulation of miR-155 by TGF-β/Smad4 195 
pathway using the Smad response elements in the human miR-155 promoter has also been 196 
reported (47). Epstein–Barr virus (EBV) latent membrane protein-1 (LMP1) is a potent 197 
inducer of miR-155 and the NF-κB sites in the Bic/miR-155 promoter have been shown to be 198 
pivotal for this function (48, 49). 199 
Both Northern blotting and microarray data showed that miR-155 is significantly increased in 200 
v-rel-transformed T and B lymphocytes compared to the normal spleen cells. These 201 
observations are similar to the findings reported previously (33). Despite the consistent 202 
demonstration of transformation of B and T-lymphocytes by v-rel, the precise mechanisms 203 
have not been demonstrated. As an NF-κB homolog (8), the most likely mechanism of miR-204 
155 upregulation would be through the direct activation of the miR-155 promoter through the 205 
NF-κB binding sites. EMSA showed that v-rel binds directly to both NF-κB binding sites. To 206 
assess the ability of v-rel to activate transcription from miR-155 promoter, we performed 207 
reporter assays using the miR-155 promoter and its derivative lacking each of the NF-κB 208 
binding sites. Our results demonstrated that indeed v-rel controls miR-155 through one of the 209 
NF-κB binding sites in the Bic/miR-155 promoter.  210 
A number of previous studies have demonstrated robust expression of Bic in EBV-infected 211 
cells (50, 51). It has been shown later that EBV-encoded latent membrane protein-1 (LMP-1), 212 
a functional homologue of the tumor necrosis factor receptor family, upregulates the 213 
expression of miR-155 mainly by activating the NF-κB pathway (48). The data here is the 214 
first evidence showing miR-155 being regulated by an NF-κB transcription factor, the v-rel 215 
oncogene encoded by Rev-T in avian systems.  It has been shown previously that v-rel exerts 216 
downstream effects through the transcription factor AP-1 (12, 46). AP-1 sites are present in 217 
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chicken Bic/miR-155 promoter sequences and the contribution of AP-1 in regulation of miR-218 
155 expression in v-rel-transformed lymphocytes remains to be determined. 219 
Interestingly, while miR-155 was upregulated in Rev-T transformed cell lines, it was 220 
consistently downregulated in MDV-transformed lymphocytes (52). Although miR-155 221 
functions are probably rescued by the high level expression of the MDV1-miR-M4 homolog 222 
in these cells (53), the precise molecular mechanisms of downregulation of miR-155 in 223 
MDV-transformed cells are not clear. RCAS-mediated transduction of v-rel did rescue the 224 
expression of miR-155 in two of the MDV transformed cell line MSB-1 and 265L. The 225 
increased level of miR-155 expression after introduction of v-rel into these cells indicated 226 
that the upregulation of miR-155 is a direct effect. It is interesting to know that common 227 
occurrence of MDV with REV in chickens could lead a part or entire genome of REV 228 
integrating into MDV genome (54, 55). Although a number of field MDV isolates with REV 229 
insertion have been characterized, the precise molecular mechanisms for the altered 230 
pathogenic properties and the increased virulence are still not clear (55, 56). 231 
A number of targets of miR-155 have been identified previously. C-Maf (43), AID (57, 58), 232 
Pu.1 (59), SOCS1 (60), interleukin-1 (61) and IKKε (49, 62) have been implicated in 233 
mediating functions of miR-155 in the immune system. Ets-1 and Meis1 mediate 234 
megakaryopoiesis (63). SHIP1 and C/EBP have been implicated in myeloproliferative 235 
disorders (64, 65), Peli1 controls the generation and function of T follicular helper cells 236 
through promoting the degradation of the NF-κB family transcription factor c-Rel (66), tumor 237 
protein p53 inducible nuclear protein 1 (Tp53INP1) is involved in pancreatic cancer (67) and 238 
SOCS1 in promoting γ-chain cytokine signalling to ensure effector and memory CD8+ T cell 239 
differentiation (68). Additionally, miR-155 targets JARID2, a cell cycle regulator and part of 240 
a histone methyltransferase complex, to promote cell survival (33). From microarray data on 241 
RNA of v-rel transformed cells, 73 out of 1242 significantly downregulated genes are 242 
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potential targets of miR-155. Not only was miR-155 the most statistically enriched target 243 
within the list of significantly down-regulated genes, but members of the miR-17-92 cluster 244 
are also implicated, a cluster which is known to be involved in cancer (69-72), this further 245 
emphasized the role of oncogenic miRNAs in transformation.   246 
The oncogenic effects of miR-155 are mediated through its target mRNAs. The known miR-247 
155 targets Pu.1, CEBPβ are present in the down regulated genes from microarray analysis in 248 
v-rel transformed cells. Together with the evidence that the potential miR-155 targets in 249 
macrophages involved in cancer are standing out of other diseases and functions related 250 
targets, demonstrating the important role of miR-155 in v-rel induced transformation. 251 
Although the precise roles and molecular pathways of miR-155 in v-rel induced 252 
transformation are not fully known, its repressive function on transcriptional factors such as 253 
Pu.1 and CEBPβ can have wide-ranging effects on the cellular milieu and the global gene 254 
expression profiles seen for lymphocytes. Further studies will be required to ascertain the 255 
involvement of Pu.1, CEBPβ and/or other miR-155 regulated transcription factors in the 256 
regulation of miR-155-inhibited genes. Similarly, the repression of some of the other target 257 
genes is also likely to contribute to the induction of hematopoietic cell malignancy. Although 258 
upregulation of miR-155 appears to add complexity to regulation of gene expression in v-rel–259 
induced malignant transformation, the downstream network of miR-155 targets or the 260 
importance of those target genes in v-rel induced transformation could be an interesting area 261 
to explore. 262 
  263 
Materials and methods 264 
Transformed cell lines  265 
  266 
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Rev-T-transformed cell lines AVOL-1 (CD4+ T-cell line) (32), AVOL-2 (B-cell origin), 267 
AVOL-3, RIR-RevT (a transformed cell line derived from outbred Rhode Island Red 268 
chickens) and avian leukosis virus (ALV) HPRS F42 strain-transformed B-cell line HP45 269 
(73) were used. MDV cell lines MSB-1 (74) and 265L (32) were used to study the effects of 270 
induction of v-rel. All the cell lines were grown at 38.5	°C in 5 % CO2 in RPMI 1640 medium 271 
containing 10 % fetal calf serum, 2 % chicken serum, 10 % tryptose phosphate broth, 0.1 % 2-272 
mercaptoethanol and 1 % sodium pyruvate. CEF-derived cell line DF-1 was grown using 273 
methods described (75).  274 
Chicken splenocytes, CD4 + T cells and magnetic cell sorting.  275 
Single-cell suspensions of lymphocytes were prepared from spleen tissues of uninfected birds 276 
by using Histopaque-1083 (Sigma-Aldrich) density-gradient centrifugation. CD4 + T cells 277 
were isolated by magnetic cell sorting using mouse anti-chicken CD4 antibodies (Chan et al., 278 
1988) and goat anti-mouse IgG microbeads (Miltenyi Biotec). After each antibody treatment, 279 
cells were washed three times with PBS containing 0.5 % bovine serum albumin. At each 280 
wash, the cell suspension was centrifuged at 450 g for 10 min. Positively stained cells were 281 
sorted through an AutoMACS Pro Separator (Miltenyi Biotec). Purity of the sorted cells was 282 
confirmed to be >99 % by flow cytometry after labelling with monoclonal anti-goat/sheep 283 
IgG–fluorescein isothiocyanate (Sigma) antibody (data not shown). 284 
Plasmid constructs  285 
The construct pcDNA3.1-v-rel was used for reporter assay. For electrophoresis mobility shift 286 
assay, recombinant v-rel fused in-frame with GST in pGEX2T (GE Healthcare) vector was 287 
used.  RCAS(A) retroviral vector (Replication Competent ALV LTR with a Splice acceptor) 288 
(76) with v-rel cloned into the ClaI site was used for in vitro transformation of embryonic 289 
splenocytes. The orientation of the insert was verified by restriction enzyme digestion and 290 
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sequencing. RCAS (A)-EGFP-v-rel construct with the N-terminal enhanced green fluorescent 291 
protein (EGFP) tag was used for the expression of v-rel in MSB-1 and 265L cells.  292 
Cloning and mutagenesis of Bic/miR-155 promoter 293 
The chicken Bic/miR-155 promoter region extending from -1829 to +3 nucleotides from 294 
transcription start site (+1) was amplified by PCR from the genomic DNA prepared from 295 
CEF. The isolated fragments were digested with BglII and NheI and cloned into BglII and 296 
NheI cut psiCHECK™-2 vector (Promega) to replace the SV40 promoter driving the renilla 297 
luciferase gene to generate the pBic-WT reporter construct. Mutagenesis of the two NF-κB 298 
sites on the pBic promoter was carried out by overlapping PCR using primers 5׳-299 
CCACATATTTCCTTGCTGGCTCGAGACATAAATTTTTCTGAG-3׳ and 5׳-300 
CTCAGAAAAATTTATGTCTCGAGCCAGCAAGGAAATATGTGG-3׳ for NF-κB site 1, 301 
5׳-GAAAAGGAAAGCAGGCTCGAGACTCAAGACGGTTAG-3׳ and 5׳-302 
CTAACCGTCTTGAGTCTCGAGCCTGCTTTCCTTTTC-3׳ for NF-κB site 2. The mutant 303 
constructs were used to replace the corresponding fragment in the pBic-WT vector to 304 
generate pBic-M1, pBic-M2 and pBic-M1M2 constructs, where the 1st, 2nd and both NF-κB 305 
sites respectively, were replaced. In each case, the XhoI restriction site introduced during the 306 
replacement of the NF-κB motifs allowed the screening of the constructs by XhoI digestion. 307 
The sequences of the promoter region of all the constructs were confirmed by sequence 308 
analysis. 309 
Dual Luciferase reporter assay 310 
Transfection of DF-1 cells was carried out with Lipofectamine 2000 (Invitrogen) as per 311 
manufacturer's protocols. Approximately 3 × 104 DF-1 cells were seeded in each well of a 96-312 
well plate. Each of the reporter and pcDNA3-v-rel constructs were co-transfected into DF-1 313 
cells and the luciferase expression was assayed 48 hours later using the Dual-Glo Luciferase 314 
Assay System (Promega) following manufacturer’s instructions. The relative expression of 315 
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renilla luciferase was determined with the normalised levels of firefly luciferase. For each 316 
sample, values from four replicates representative of at least two independent experiments 317 
were used in the analysis. 318 
Electrophoresis mobility shift assay (EMSAs) 319 
Recombinant full length v-rel from pGEX2t-v-rel plasmid in BL21 (DE3) induced with 0.5 320 
mM isopropyl-b-D-thiogalactopyranoside (IPTG) for 3h was purified by Glutathione 321 
Sepharose 4 Fast Flow (GE Healthcare) according to the manufacturer’s instructions. EMSAs 322 
were performed using gel shift assay system (Promega) according to the manufacturer’s 323 
instructions. Double-stranded synthetic oligonucleotides were radiolabeled using [γ32P] ATP 324 
(Amersham) and T4 polynucleotide kinase. For each binding reaction, 3µg of purified protein 325 
was incubated with 0.25µg/µl poly[dI-dC] containing 50,000cpm of  radiolabelled probes and 326 
a 50-fold molar excess of unlabelled competitor oligonucleotide when indicated. DNA-327 
binding reactions were carried out for 30 min at room temperature. Competition experiments 328 
were performed by pre-incubation with protein in binding buffer for 10 min, after which 329 
labelled probe was added for a further 20-min incubation at room temperature. The DNA-330 
protein complexes were resolved on 6% DNA Retardation Gel (Invitrogen) and detected by 331 
autoradiography. 332 
Immunoblotting and Northern blotting 333 
For Western blotting, cells were lysed in protein gel sample buffer (8	M urea, 2 % SDS, 10	334 
mM Tris/HCl pH	6.8, 0.05 % bromophenol blue) and separated on a NuPAGE 4–12 % Bis 335 
Tris gel (Invitrogen) and transferred onto nitrocellulose membranes using an iBlot gel 336 
transfer system (Invitrogen). Western blotting was performed with c-rel and v-rel-specific 337 
HY87 mouse monoclonal antibody (77), followed by anti-mouse IgG–peroxidase conjugate 338 
(Sigma-Aldrich). Membranes were developed with an ECL Western blotting analysis system 339 
(Amersham). For Northern blot analysis, total RNA was extracted from cultured cells with 340 
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miRNeasy Mini Kit (Qiagen), and 20	µg total RNA resolved using a 15 % polyacrylamide-341 
1×Tris-borate-EDTA-8	M urea gel was blotted to a GeneScreen Plus membrane (Perkin-342 
Elmer). DNA oligonucleotides with sequences complementary to candidate miRNAs, end-343 
labelled with [γ-32P]ATP (Amersham) using T4 polynucleotide kinase (New England 344 
Biolabs), were used as high-specific-activity probes. Hybridization, washing and 345 
autoradiography were carried out as previously described (78).   346 
RCAS virus infection 347 
Virus stocks generated from DF-1 cells transfected with RCAS(A)-v-rel and RCAS(A)-v-rel-348 
EGFP constructs approximately 5 days after transfection, when nearly 100% cells were 349 
EGFP positive in the case of the latter construct. For in vitro transformation assay, one ml 350 
(~106 TCID50) of RCAS(A)-v-rel virus was used to infect 5x106 of embryonic splenocytes, 351 
and harvested at day 0, 1, 4, 7, 9 and 14 days post infection for mRNA microarray analysis 352 
and miR-155 quantitation. EGFP-expressing RCAS(A)-v-rel-EGFP-infected MSB-1 and 353 
265L cells were also sorted and examined for v-rel and miR-155 expression.  354 
Stem-loop qRT-PCR for miR-155 355 
The expression levels of miR-155 were analysed using the TaqMan MicroRNA Assay 356 
System (Applied Biosystems) using 10 ng of total RNA as a template for reverse 357 
transcription. Each reverse transcription reaction was performed twice independently, and 358 
each reaction was tested by PCR in triplicates. All values were normalized to the expression 359 
of the endogenous let-7a, and levels calculated as fold-expression change relative to those 360 
from uninfected 265L cells.  361 
Microarray Analysis 362 
Triplicate RNA samples for each of the six time-points (0, 1, 3, 4, 7 and 14 dpi) were 363 
analysed using the Affymetrix GeneChip Chicken Genome Array.  Expression values were 364 
calculated using the Robust Multi-Array Average (RMA) function within the Affy 365 
Page | 16 
 
bioconductor package (79).  Affymetrix probes were linked to Ensembl genes using Ensembl 366 
(v70) and genes linked to microRNA predicted targets data from the MicroCosm targets 367 
database (80) 368 
For the naïve prediction of miRNAs involved in the activation of genes from the mRNA 369 
expression data, the following analysis was performed: down-regulated probes at 14 DPI 370 
compared to 0 DPI were determined using Limma (35), with a FDR<=0.01 (81) and log fold 371 
change <= -1 (two-fold down-regulated).  Statistical enrichment of miRNA targets within the 372 
down-regulated gene list was calculated using the CORNA package (82).  Fisher’s exact test 373 
was used to calculate p-values for statistical enrichment, and adjusted for multiple testing 374 
(81). Heatmaps were drawn in R using the Pearson correlation coefficient as a similarity 375 
measure (83). 376 
In order to analyse the behaviour of predicted gga-miR-155 targets, expression data from 377 
Affymetrix probes representing genes predicted to be targets of gga-miR-155 were extracted 378 
and analysed as a set.   379 
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Table 1 Top 20 enriched miRNA targets in the list of 1242 downregulated genes 614 
microRNA 
Numbers of miRNA target genes in the population 
FDR4 
Predicted1 Expected2 Observed3 
gga-mir-155 581 45 73 0.002** 
gga-mir-9* 504 39 65 0.002** 
gga-mir-217 603 46 69 0.033** 
gga-mir-19a 648 50 72 0.045** 
gga-mir-23b 633 49 70 0.045** 
gga-mir-106 685 53 74 0.055 
gga-mir-137 570 44 63 0.065 
gga-mir-20a 727 56 77 0.065 
gga-mir-124b 557 43 61 0.065 
gga-mir-190 549 42 60 0.069 
gga-mir-19b 629 48 67 0.069 
gga-let-7k 623 48 66 0.077 
gga-mir-466 806 62 82 0.080 
gga-mir-17-5p 732 56 75 0.095 
gga-mir-302b 652 50 67 0.114 
gga-mir-135a 646 50 66 0.115 
gga-mir-29b 692 53 70 0.115 
gga-mir-124a 577 44 60 0.115 
gga-mir-153 621 48 64 0.115 
gga-mir-146b* 490 38 24 0.122 
1Predicted: The total number of genes predicted to be targets of the microRNA in the 615 
population; 2Expected: The number we would expect to see in our sample by random chance 616 
based on our sample size; 3Observed: The number we actually observed; 4FDR: The 617 
Benjamini and Hochberg adjusted p-value from a two-tailed Fisher's exact test.  **indicates 618 
FDR <= 0.05 619 
620 
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Figure legends 621 
Figure 1. Northern blotting analysis for determining miR-155 expression. Twenty 622 
micrograms of total RNA extracted from the indicated cells was separated on a 15 % 623 
denaturing polyacrylamide gel, blotted and hybridized with end-labelled antisense 624 
oligonucleotide probes to gga-miR-155. Size markers to indicate the positions of the pre-625 
miRNA and the mature miRNA are shown. The cellular U6 small nuclear RNA served as the 626 
loading control. 627 
 628 
Figure 2. Activation of miR-155 by v-rel occurs through the NF-κB pathway.  (A) 629 
Electrophoresis mobility shift assay using purified v-rel on the two putative NF-κB binding 630 
sites NF-κB1 (−581) and NF-κB2 (−66) on the chicken Bic/miR-155 promoter. WT = 50-fold 631 
molar cold wild-type competitor, mu = 50-fold molar cold mutant competitor. (B) Schematic 632 
diagram of luciferase reporter constructs carrying the wild type (WT) and mutant (M1, M2 633 
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and M1M2) chicken Bic/miR-155 promoter. (C) Relative levels of luciferase in DF-1 cells 634 
co-transfected with pcDNA3-v-rel and the reporter constructs. Error bars represent the data 635 
from 4 replicates. 636 
 637 
Figure 3. Upregulation of miR-155 in MDV-transformed cell lines by v-rel. (A) Cell 638 
lysates from MSB-1 and 265L infected with RCAS(A)-v-rel-GFP were analysed by Western 639 
blot using HY87 antibody for v-rel expression. Uninfected MSB-1 and 265L were included 640 
as negative control and AVOL-1 cells were included as positive control. (B) Expression 641 
levels of miR-155 in RCAS(A)-v-rel-GFP infected and uninfected MSB-1 and 265L. 642 
RCAS(A)-GFP infected cells were also included as a control. 643 
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 644 
Figure 4. Upregulation of miR-155 during v-rel transformation is associated with 645 
downregulation of targets. (A) Expression levels of miR-155 in RCAS(A)-v-rel 646 
transformed embryonic splenocytes on RNA samples harvested on day 0, 1, 4, 7, 9 and 14 647 
days post infection. (B) Heatmap of 73 down-regulated genes predicted to be targets of gga-648 
miR-155.  Affymetrix probes were analysed using Limma, comparing d14 to d0 and those 649 
with an FDR<=0.01 and fold-change <= -1 (two-fold) selected.  The list was further filtered 650 
for those genes predicted to be targeted by gga-miR-155.  Heatmap was drawn in R using the 651 
Pearson correlation coefficient as a distance measure. 652 
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Figure 5. The potential miR-155 targets are involved in a number of dieases and 654 
functions. Top 20 functions (sorted by p-value) of the miR-155 targets identified in primary 655 
avian macrophages transfected with miR-155 mimics.  The grey bars indicate the number of 656 
potential target genes for each disease or function. 657 
 658 
